The company said it is evaluating its strategic options regarding ADX-097 as it shifts efforts over to pushing bempikibart.

inhibitor for adolescents with severe alopecia areata (AA), offers distinct properties that make it suitable for younger patients, and how its introduction influences treatment decisions and ...

Alopecia refers to hair loss and can affect the scalp, eyebrows, eyelashes, and other areas of the body. There are different types of alopecia including an | Immunology ...

Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune homeostasis, today announced a corporate restructuring to ...

Atopy from food allergies to environmental factors can increase hair loss prevalence among children and adults, according to ...

WALTHAM, Mass. - Q32 Bio Inc. (NASDAQ: QTTB), a clinical-stage biotechnology firm trading at $3.18 with a market cap of $38.55 million, announced a strategic shift to prioritize the development of its ...

Q32 Bio (Nasdaq: QTTB) has announced a corporate restructuring, shifting its focus entirely to the development of its lead ...

While there's no conclusive evidence that diet causes alopecia areata, some people say that diet can trigger or worsen it. Alopecia areata is an autoimmune disease that happens when the immune system ...

In Japan, about 2 percent of the population has alopecia areata, with the number of patients on the rise. Anyone, regardless of age and gender, can develop symptoms. As they become severe ...

Pfizer’s JAK/TEC inhibitor Litfulo has been recommended for NHS use as a treatment for hair loss caused by severe alopecia areata, the first drug therapy for a condition that affects around ...

Q32 Bio (QTTB) announced a corporate restructuring to focus on the advancement of its bempikibart clinical development program for the ...